Research updates, business developments, and important news from the psychedelic therapy and wellness industry.
Follow this category for clinical, policy, and business signals that affect access to supervised psychedelic care. Start with the psilocybin therapy guide for the full protocol, then compare supervised psilocybin with ketamine therapy and the broader psilocybin vs MDMA vs ketamine treatment landscape.
Recent industry posts track 2026 therapy trends, therapy cost, and common mistakes to avoid. For treatment-fit questions, use the conditions hub.
The most important signals to watch are trial quality, real-world access, cost, and safety screening. A headline about growth is more useful when it tells you who can access care, who should avoid it, and what support happens before and after the session. For safety context, review SSRIs, lithium, and MAOI interaction guidance.
17 posts in Industry News
Chacruna and Brooklyn Psychedelic Society are throwing a benefit dance party in Bushwick on October 17. It makes no claims about law or science — but the field it celebrates has moved faster in Washington this year than in the journals, and that gap is worth naming out loud.
On October 5, 2026, MAPS announced a partnership with the International Alliance of Psychedelic Therapy Practitioners to build "clinical and ethical standards." The release names no curriculum, no hours, no cost, and no credential — and it landed on the exact day FDA's comment window closed on the same question. Meanwhile the first peer-reviewed safety data out of Oregon suggests facilitators reported one of four serious adverse reactions.
A Psychedelics Today video title asks whether psychedelic higher education is ready. The documents underneath it answer: FDA spent 2026 asking who should legally be qualified to sit in a dosing room, and the training industry that grew up ahead of that decision has no outcome evidence at all. Here is what a $9,400 certificate actually buys.
Psychedelics Today hosted a livestream on "community-led psychedelic media" on September 23, 2026. We could not watch it, so we did the other job: checking who funds the outlets covering psilocybin, and whether the evidence underneath the headlines holds up. Short version — the loudest claims rest on company press releases, one uncontrolled 30-person study, and an executive order that changed nothing about federal law.
The Chacruna Institute ran a free forum on September 23, 2026 called "Building Tripsafe Communities." It contained no data — but the work its speakers do does. Here is what the published record says about psilocybin harms, and about whether harm-reduction services demonstrably reduce them.
A DoubleBlind Short put the question back in circulation: is natural psilocybin better than synthetic? The honest answer is that two lines of preclinical evidence say maybe, no human trial has ever tested it, and every FDA-track program runs on synthetic anyway.
Governor González-Colón signed EO 2026-037 to study whether Puerto Rico can host trials of ibogaine, psilocybin, and MDMA. Veterans are named first. The order does not legalize therapy or authorize routine clinical use.
Psychiatrist Dr. Tracey Marks explains how a clinical psilocybin dose can quiet rumination, reopen a plasticity window, and why that is not the same thing as a take-home mushroom pill.
Johns Hopkins professor Matthew Johnson explains why a 30–40mg “heroic dose” of psilocybin can feel life-changing — and why the container around it matters more than the milligrams.
A 2026 Nature Communications study in psychedelic-naïve adults found measurable brain-network and white-matter changes lasting at least a month after a single 25mg psilocybin session.
From COMP360's Phase 3 milestone to Colorado's rapid scale-up and MDMA's FDA resubmission, these are the five psychedelic therapy developments worth tracking in 2026.
Legal psilocybin therapy in Oregon or Colorado costs $1,500–$3,500 per complete experience. Retreats abroad run $3,000–$8,000+. Here's exactly what drives cost, what's included, and how to reduce it.
Most problems in psilocybin therapy are preventable. Here are the seven most common mistakes — stopping SSRIs abruptly, skipping integration, choosing an unverified facilitator — and exactly what to do instead.
From sub-perceptual microdoses to high-dose sessions, dose strongly shapes outcomes. We break down the evidence by dose range and what it means for therapy and personal use.
Early studies suggest that auditory stimulation and psilocybin may each influence brain rhythms and plasticity. We look at what's known and what's speculative in the context of Alzheimer's and cognitive decline.
Researchers find significant and lasting reductions in depression symptoms after just two guided psilocybin sessions.
As legal access expands, advocates push for insurance coverage. Here's where the conversation stands in 2026.